Psychedelic Bulletin #126: Journey’s Mescaline Patent Pledge; Therapeutic Alliance Doesn’t Predict Response to Psilocybin Therapy, Says COMPASS

This Week: Journey’s Patent Pledge Marks First for Psychedelics Space Predicting Response to Psilocybin Therapy: Therapeutic Alliance Not Relevant, Says COMPASS Macro Trend: The Inflation Reduction Act’s Impact on Drug Development Psychedelic CPT Codes to Be Considered in February and lots more… Journey’s Patent Pledge Marks First for Psychedelics Space Psychedelic drug developer Journey Colab has…

Source